Unicycive Therapeutics (UNCY) Short-term Investments (2025 - 2026)
Unicycive Therapeutics (UNCY) reported Short-term Investments of $17.2 million for Q1 2026, up 42.61% quarter-over-quarter from $12.1 million in Q4 2025.
Unicycive Therapeutics (UNCY) Short-term Investments (2025 - 2026) Analysis & Trends
Unicycive Therapeutics has reported Short-term Investments for 2 years, with the latest figure at $17.2 million in Q1 2026.
- For the quarter ending Q1 2026, Short-term Investments changed N/A year-over-year to $17.2 million; the trailing twelve-month figure through Mar 2026 stood at $17.2 million (changed N/A YoY), and the FY2025 full-year result was $12.1 million, changed N/A from the prior year.
- Short-term Investments for Q1 2026 stood at $17.2 million, up from $12.1 million in the prior quarter.
- The five-year high for Short-term Investments was $17.2 million in Q1 2026, with the low at $12.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Unicycive Therapeutics | 174.05 Mn | 119.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.22 Mn |
| Dec 31, 2025 | 12.07 Mn |